Abstract
Objective: To investigate the inhibitory effects and the mechanism of NF-κB decoy oligodeoxynucleotides (ODN) on Kupffer cells (KCs) activation.
Methods: KCs were isolated and randomly divided into three groups: (1) a control group; (2) an LPS stimu1ation group and (3) an NF-κB decoy group, in which the KCs were transduced with an NF-κB decoy ODN prior to LPS stimulation. Following 6 hours of LPS stimulation, the NF-κB activity was assayed by an electrophoretic mobility shift assay (EMSA). The CD80 mRNA expression in the KCs was detected by reverse transcription-polymerase chain reaction (RT-PCR), and the production of TNF-α and IL-6 in the supernatant was measured by an enzyme-linked immune sorbent assay (ELISA).
Results: The NF-κB decoy ODN could efficiently inhibit KCs activation by LPS stimulus. The NF-κB activity was significantly decreased to 0.53 fold as compared with the LPS group. The CD80 mRNA expression, TNF-α production, and IL-6 level were significantly decreased to 0.46, 0.37, and 0.60 fold, respectively.
Conclusion: The NF-κB decoy ODN could efficiently suppress transcription activity of NF-κB and inhibit co-stimulatory molecules and cytokines expression by KCs, which afford reliable experimental data for the in vivo application of NF-κB decoy ODN.
Keywords: Cytokines, Kupffer cells, LPS, NF-κB, oligodeoxynucleotides, TNF-α.
Current Signal Transduction Therapy
Title:NF-κB Decoy Oligodeoxynucleotides Inhibits Kupffer Cell Activation
Volume: 10 Issue: 1
Author(s): Chun Huang, Shan-mao Nie, Yi-ming Liu, Min Li, Jian-ping Gong and Meng-hao Wang
Affiliation:
Keywords: Cytokines, Kupffer cells, LPS, NF-κB, oligodeoxynucleotides, TNF-α.
Abstract: Objective: To investigate the inhibitory effects and the mechanism of NF-κB decoy oligodeoxynucleotides (ODN) on Kupffer cells (KCs) activation.
Methods: KCs were isolated and randomly divided into three groups: (1) a control group; (2) an LPS stimu1ation group and (3) an NF-κB decoy group, in which the KCs were transduced with an NF-κB decoy ODN prior to LPS stimulation. Following 6 hours of LPS stimulation, the NF-κB activity was assayed by an electrophoretic mobility shift assay (EMSA). The CD80 mRNA expression in the KCs was detected by reverse transcription-polymerase chain reaction (RT-PCR), and the production of TNF-α and IL-6 in the supernatant was measured by an enzyme-linked immune sorbent assay (ELISA).
Results: The NF-κB decoy ODN could efficiently inhibit KCs activation by LPS stimulus. The NF-κB activity was significantly decreased to 0.53 fold as compared with the LPS group. The CD80 mRNA expression, TNF-α production, and IL-6 level were significantly decreased to 0.46, 0.37, and 0.60 fold, respectively.
Conclusion: The NF-κB decoy ODN could efficiently suppress transcription activity of NF-κB and inhibit co-stimulatory molecules and cytokines expression by KCs, which afford reliable experimental data for the in vivo application of NF-κB decoy ODN.
Export Options
About this article
Cite this article as:
Huang Chun, Nie Shan-mao, Liu Yi-ming, Li Min, Gong Jian-ping and Wang Meng-hao, NF-κB Decoy Oligodeoxynucleotides Inhibits Kupffer Cell Activation, Current Signal Transduction Therapy 2015; 10 (1) . https://dx.doi.org/10.2174/1573407211666150603201802
DOI https://dx.doi.org/10.2174/1573407211666150603201802 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Adrenomedullin in Hypertension
Current Hypertension Reviews Recent Advances in Ethnopharmacological and Toxicological Properties of Bioactive Compounds from <i>Aloe barbadensis</i> (Miller), <i>Aloe vera</i>
Current Bioactive Compounds Clinical Applications of Creatine Supplementation on Paediatrics
Current Pharmaceutical Biotechnology Oxidative and Nitrosative Stress and Immune-inflammatory Pathways in Patients with Myalgic Encephalomyelitis (ME)/Chronic Fatigue Syndrome (CFS)
Current Neuropharmacology IP6 (Inositol Hexaphosphate) as a Signaling Molecule
Current Signal Transduction Therapy Stem Cell Therapy for Ischaemic Stroke: Translation from Preclinical Studies to Clinical Treatment
CNS & Neurological Disorders - Drug Targets Role of Endothelial Nitric Oxide in Cerebrovascular Regulation
Current Pharmaceutical Biotechnology FTY720 (Fingolimod) Ameliorates Brain Injury through Multiple Mechanisms and is a Strong Candidate for Stroke Treatment
Current Medicinal Chemistry Adrenomedullin Function in Vascular Endothelial Cells: Insights from Genetic Mouse Models
Current Hypertension Reviews Epigenetic Mechanisms and Kidney Diseases
Current Medicinal Chemistry NADPH Oxidases and Inflammatory Bowel Disease
Current Medicinal Chemistry Microvascular Diseases: Is A New Era Coming?
Cardiovascular & Hematological Agents in Medicinal Chemistry Triiodothyronine (T3) Effects on Cardiovascular System in Patients with Heart Failure
Recent Patents on Cardiovascular Drug Discovery The Role of T and B Cells in Atherosclerosis: Potential Clinical Implications
Current Pharmaceutical Design The Role of the RhoA/rho-kinase Pathway in Pulmonary Hypertension
Current Drug Discovery Technologies Role of Statins in Peri-Operative Medicine
Current Drug Targets A Review of Patents Relating to Therapeutic Angiogenesis Using Endothelial Progenitors and Other Vasculogenesis-Related Cell Types
Recent Patents on Regenerative Medicine Multivalent & Multifunctional Ligands to β-Amyloid
Current Pharmaceutical Design Anesthetic Neuroprotection: Antecedents and An Appraisal of Preclinical and Clinical Data Quality
Current Pharmaceutical Design Mitochondrial Dysfunction and Targeted Drugs: A Focus on Diabetes
Current Pharmaceutical Design